To start your customized experience click the start button
Customize ?  
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Bladder Cancer

Kristie L. Kahl
With no available diagnostic tests for the detection and/or monitoring of bladder cancer, researchers from the Medical College of Georgia at Augusta University may have two new urine tests that determine the disease’s severity and detect for its recurrence.
Alexandra Guadagno
May is recognized as Bladder Cancer Awareness Month. Know the facts and statistics in order to understand your risk for the disease and take preventative actions to guard your health.
Kristie L. Kahl
A recent study showed that postmenopausal women demonstrated a significant reduction in the risk for bladder cancer after quitting smoking, highlighting the need for prevention and cessation programs in older women.
Kristie L. Kahl
Researchers at Baylor College of Medicine found that a particular subgroup of patients with advanced bladder cancer, identified with a computational tool, responded to immunotherapy.
Katie Kosko
A person’s pre-existing mental state may negatively influence their health, but professional support can help maintain the best mindset, say researchers.
Katie Kosko
Researchers found that women who went into menopause before 45 years old were at greater risk for bladder cancer than women who experienced it later.
Jessica Skarzynski
After more than 30 years of relative stability, the treatment landscape for urothelial cancer has seen updates in recent years that provide hope for patients.
Kristie L. Kahl
According to survey results, almost 30% of non-muscle invasive bladder cancer survivors experienced at least one PTSD symptom.
Alexandra Guadagno
The Food and Drug Administration granted accelerated approval to Balversa to treat locally advanced or metastatic bladder cancer with a type of susceptible genetic alterations known as FGFR3 or FGFR2, in patients who have progressed during or following prior platinum-containing chemotherapy.
Katie Kosko
A percentage of patients with urothelial carcinoma saw their disease shrink or disappear after treatment with enfortumab vedotin in a phase 2 clinical trial.

Sign In

Not a member? Sign up now!
Continue without login

Sign Up

Patient Caregiver Advocate Other